Merck Stock (NYSE:MRK) Upgraded To Buy

HSBC analysts have recently boosted their recommendation on Merck shares (NYSE: MRK) to a Buy rating, moving up from a previous Hold. This upgrade is accompanied by a maintained price target of $130. The analysts base this decision on Merck’s strategic approach towards imminent patent expirations and its robust position in oncology.

Merck’s strategy focuses on extending the earnings potential of its oncology portfolio. This is especially significant given the company’s expertise in oncology and a strong clinical pipeline. As clinical successes become evident, analysts expect increased recognition of Merck’s pipeline value.

In 2025, Merck faces several notable opportunities, the stabilisation of Gardasil’s revenue in China could be a significant contributor, the progress on subcutaneous formulations of Keytruda could provide additional market advantages, and the introduction of Winrevir presents further growth prospects

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

HSBC’s analysis of Merck highlights a balanced view of imminent opportunities and risks. The upgrade to a Buy rating reflects confidence in Merck’s strategic direction and its capacity to manage upcoming challenges effectively. While risks remain, particularly related to its product pipeline and market conditions, Merck’s efforts in oncology and strategic innovations signify positive long-term prospects.